Allergic asthma can vanish over time either spontaneously or induced by allergen-specific immunotherapy. In mice with established airway allergic inflammation, chronic intranasal (IN) allergen challenges decreases progressively airway allergic inflammation. Here we compared the contribution of different regulatory pathways that could be associated with this phenomenon, known as local inhalational tolerance. We found that inhalational tolerance was not associated with increased number of regulatory Tcells or suppressive cytokines. Instead, it was associated with increased apoptosis of airway inflammatory leukocytes revealed by annexin-V staining and the expression of apical caspase 8 and effector caspase 3. Also, the transition from acute to chronic phase was associated with a shift in the expression of pro-allergic to pro-apoptotic molecules. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was found to be a key molecule in mediating resolution of allergic inflammation because anti-TRAIL treatment blocked apoptosis and increased the infiltration of T helper type 2 (Th2) cells and eosinophils. Notably, repeated IN treatment with recombinant TRAIL in established airway allergic inflammation augmented leukocyte apoptosis and decreased the frequency of interleukin-5-producing Th2 cells and eosinophils to airways. Our data indicate that TRAIL signaling is sufficient for downmodulation of allergic airway disease, suggesting a potential therapeutic use of TRAIL for asthma treatment.
INTRODUCTION
Allergic asthma is a chronic inflammatory disease characterized by airway eosinophilia, airway hyperreactivity, mucus hypersecretion, and high titers of immunoglobulin E (IgE) (1) . T helper type 2 (Th2) lymphocytes are thought to be responsible for the initiation, progression, and persistence of the disease because upon allergen challenge they secrete type-2 cytokines such as interleukin-4 (IL-4), IL-5, IL-9, and IL-13 that mediate the Th2-associated inflammatory network and IgE production. [1] [2] [3] [4] However, not all individuals develop allergy upon exposure to allergens and some patients can resolve it over time either spontaneously or by repeated allergen challenges that is the basis of specific immunotherapy. [5] [6] [7] [8] Therefore, the immune system has evolved regulatory mechanisms to control allergic responses to harmless noninfectious antigens. Murine models have been developed to study either effector or immune regulatory mechanisms operating in allergic lung disease. [9] [10] [11] [12] [13] [14] One well-characterized murine model of immune regulation that leads to resolution of allergic airway inflammation consists of given long-term IN allergen challenges to sensitized mice. [15] [16] [17] [18] This phenomenon, known as local inhalational tolerance, is characterized by local resolution of allergic airway inflammation because it courses along with persistent systemic IgE production. [19] [20] [21] Various studies using this model suggested different mechanisms for the resolution of allergic inflammation such as the emergence of Foxp3 þ CD25 þ CD4 regulatory T (Treg) cells, [22] [23] [24] or regulatory B cells, 25 or a population of transforming growth factor (TGF)-b 1 -expressing macrophages. 26 Although these studies were well conducted, none of them compared the specific contribution of these different regulatory pathways.
Generally, resolution of inflammation might involve suppressive mechanisms that inhibit the action of inflammatory cells and/or the release of inflammatory mediators or induction of apoptosis of effector cells. Here we evaluated whether Treg cells, suppressive cytokines, or apoptosis could be associated with the inhalational tolerance. For this, we treated mice with specific monoclonal antibodies (mAbs) to block functionally key molecules involved in regulatory/suppressor activities or apoptotic process. mAb directed to inactivation of Treg cell function or TGF-b were without effect. However, neutralizing mAb directed to members of the tumor necrosis factor (TNF) superfamily of death-inducing ligands, such as Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL), or to programmed cell death protein-1 (PD-1), a protein of immunoglobulin superfamily, revealed that the TRAIL pathway was critically involved in the resolution of allergic inflammation induced by long-term ovoalbumin (OVA) administration given at weekly intervals.
RESULTS

Resolution of allergic inflammation induced by long-term allergen challenges is restricted to the lung
Acute exposure of sensitized mice to inhaled antigen elicits airway eosinophilia and elevation of serum IgE. Conversely, chronic allergen exposure leads to resolution of airway inflammation but persistent antibody production (Supplementary Figure S1 online), a phenomenon termed as local inhalational tolerance. 19 Here we extended this observations and studied the effects of prolonged antigen exposure on two different sites of sensitized mice, the airways and peritoneal cavity. For this, we established the acute allergic and chronic tolerant protocols monitoring the eosinophilic inflammation of the airways and the systemic IgE production 24 h after each antigen challenges given at weekly intervals for a period of 5 weeks. As shown in Figure 1 , the number of eosinophils in the bronchoalveolar lavage (BAL) fluid started to increase 24 h after the first OVA challenge, reaching maximum values after the third challenge, but decreasing thereafter (Figure 1a) . In contrast, the serum levels of IgE increased progressively up to the second OVA challenge and remained elevated thereafter ( Figure 1b) . Next we compared in sensitized mice the effects of prolonged OVA challenges given concomitantly in the airways and peritoneal cavity as depicted in Figure 1c . We termed the group of mice exposed to two OVA challenges as acute and the group of mice exposed to five OVA challenges as chronic (Figure 1c) . We found that the number of eosinophils increased in BAL and in peritoneal cavity after acute exposure to OVA ( Figure 1d ). As expected, chronic IN OVA exposure resulted in a drastic reduction of eosinophils in the BAL (Figure 1d ). However, in sharp contrast with OVA airway challenges, chronic IP OVA did not decrease eosinophil influx to peritoneal cavity when compared with acute OVA exposure (Figure 1d) . These results clearly indicated that the resolution of allergic inflammation induced by long-term allergen challenges depends on the site where OVA is given and effectively occur at mucosal surface but not in the serosal cavity.
Treg cells and suppressive cytokines do not mediate the resolution of allergic airway inflammation
It has been reported that the resolution of allergic airway inflammation or airway hyperreactivity induced by long-term allergen challenge is associated with local accumulation of Treg cells. 22, 23 Therefore, we evaluated the percentage and number of Foxp3 þ CD4 þ T cells in the airways and draining lymph nodes of mice that received inhaled OVA acutely or chronically. We found that Foxp3 þ CD4 þ T cells were increased in the BAL and in lungs of acute but not chronic mice, whereas the number of Treg cells in the mediastinal draining lymph node was increased similarly in acute and chronic groups (Figure 2a Figure S2d) , indicating that airway Treg cells are associated with allergic inflammation rather than with inhalational tolerance. We also assessed the function of Treg cells in vivo by treating the animals with anti-CD25 (PC61) mAb to deplete and/or to inactivate putative CD25
þ Treg cells as shown previously by us and others. [27] [28] [29] [30] During acute OVA challenge, the anti-CD25 mAb treatment increased the number of eosinophils in the BAL when compared with animals non-treated (phosphate buffered saline (PBS) group) (Figure 2b ) or treated with isotype control rat IgG1 mAb (GL113) (data not shown). However, during chronic OVA challenge, the anti-CD25 treatment did not change the lung tolerant state as evidenced by reduced number of eosinophils in the BAL (Figure 2b) . Altogether, these results indicate that Treg cells are not involved in the suppression of lung allergic inflammation induced by chronic OVA challenges.
Because suppression of allergic airway inflammation has also been attributed to the production of IL-10 and TGF-b, 26, 31, 32 we measured the content of these suppressive cytokines in the airways. We found that the levels of IL-10 in the BAL and the frequency of IL-10-producing Foxp3 -
CD4
þ T cells, but not Foxp3 þ Treg cells, in the lungs were increased during acute but not chronic OVA challenges (Figure 2c and Supplementary  Figure S2e ), indicating that IL-10 is more associated with acute allergic inflammation than local inhalational tolerance. In addition, experiments performed in IL-10-deficient mice confirmed that IL-10 is dispensable for the induction of local inhalational tolerance as IL-10-deficient mice developed it normally (Supplementary Figure S2f) . Next, we measured the levels of total and bioactive TGF-b and found that they were increased in the BAL of mice that received acute or chronic OVA challenges (Figure 2c ). We also determined by flow cytometry cells expressing latency-associated peptide (LAP), which indirectly detect the TGF-b-producing cells. 33 We found that lung CD11c has an important role in airway remodeling, 34 we also investigated the lung collagen deposition in acute and chronic mice. Masson staining of lung sections revealed an increase of peribronchial and perivascular collagen deposition in mice with 
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MucosalImmunology | VOLUME 7 NUMBER 5 | SEPTEMBER 2014 both acute and chronic-inhaled OVA (Figure 2f,g ). Notably, lung collagen deposition was significantly inhibited in chronic mice treated with anti-TGF-b when compared with nontreated PBS group (Figure 2f,g ), indicating that the mAb is biologically active. We concluded that TGF-b is not involved in inhibition of allergic inflammation. All in all, these results clearly show that Treg cells or suppressive cytokines IL-10 and TGF-b do not mediate the resolution of allergic airway inflammation induced by long-term allergen challenge.
Apoptosis of airway leukocytes increases during chronic OVA exposure
Accumulating evidence indicate that apoptosis (programmed cell death) has a key role in the resolution of inflammatory processes and re-establishment of tissue homeostasis. 35, 36 Therefore, we determined annexin-V staining, a marker of apoptotic cells, on infiltrating airway leukocytes during acute or chronic exposure to OVA. As shown in Figure 3 , the frequency of annexin-V þ PI -apoptotic cells was higher during the chronic OVA exposure than during acute exposure. Indeed, the percentage of apoptotic cells during chronic OVA exposure was roughly twofold higher than during acute exposure (Figure 3a,b) . Notably, different cell types such as CD4
, and MHCII þ CD11b þ cells stained positively for annexin-V (Supplementary Figure S3) , indicating that different cells rather than a specific cell type are undergoing apoptosis during chronic OVA. Apoptosis can be initiated by the activation of cell-surface death receptors belonging to the TNF receptor superfamily such as Fas and TRAIL receptors or by PD-1 of the immunoglobulin superfamily. [37] [38] [39] Thus, we determined the expression of members of death-inducing ligands as well as pro-allergic or modulatory and effector molecules of apoptosis. As shown in Figure 3c , the mRNA expression of TRAIL (Tnfsf10) and PD-1 ligand (CD274) was higher in acute than in chronic group, whereas the expression of FasL (Tnfsf6) was higher in chronic group. Interestingly, two molecules associated with TRAIL signaling were differentially expressed in acute and chronic group. The expression of pro-allergic E3 ubiquitin ligase midline 1 (MID1) 40 was highly expressed in acute group, whereas the expression of insulin-like growth factor-binding protein-3, a pro-apoptotic molecule 41, 42 predominated in chronic mice (Figure 3d) . Finally, the expression of apical (casp8 (caspase 8)) and effector (casp3) caspases was only observed in chronic mice, whereas the expression of the initiator casp9 that is involved in the intrinsic or mitochondrially gated pathway of apoptosis 43 was significantly increased in acute group (Figure 3e) . Overall, the above results indicate that an active extrinsic apoptotic process is operating in chronic mice.
Inhibition of apoptosis restores allergic airway inflammation
To further investigate the apoptotic process, we treated chronic mice with five IN injections of anti-FasL, anti-TRAIL, or anti-PD-1 during the last two OVA challenges. We found that anti-TRAIL treatment, but not anti-FasL or anti-PD-1, markedly reduced the percentage of annexin-V þ PI -apoptotic cells in the BAL of chronic mice when compared with PBS group (Figure 4a,b) . Notably, the number of eosinophils and neutrophils increased in the BAL of chronic mice treated with anti-TRAIL when compared with those treated with antiFasL, anti-PD-1, or PBS (Figure 4c-e) . The number of eosinophils found in BAL of chronic mice treated with anti-TRAIL reached similar levels to that seen during acute OVA challenge (Supplementary Figure S4a) . In addition to increased number of eosinophils in BAL, lung inflammatory cell infiltrates and mucus production were higher in chronic mice treated with anti-TRAIL than those treated with antiFasL, anti-PD-1, or PBS (Figure 4f,g ). We confirmed that FasL was dispensable for the resolution of allergic inflammation in OVA-sensitized mice carrying spontaneous mutations in the fas gene (Supplementary Figure S4b) . These results indicate that chronic OVA challenge triggers the TRAIL pathway of apoptosis that is associated with the resolution of allergic lung inflammation. (Figure 5d) . Notably, the percentage of CD4 þ T cells producing IL-5, but not IL-4, was augmented in the lungs of chronic mice treated with anti-TRAIL when compared with PBS group (Figure 5e-g) . Indeed, the frequency of activated Th2 cells found in anti-TRAIL-treated group was similar to that obtained in the lungs of acute mice (Supplementary Figure S5a-d) . Taken together, our results indicate that blockade of TRAIL signaling during long-term allergen challenges augments activated Th2 cells in the lung and promotes allergic airway inflammation.
Treatment with recombinant TRAIL augments apoptosis and attenuates Th2-mediated allergic lung inflammation
To determine directly the anti-allergic effect of TRAIL signaling in vivo, we treated allergic mice during acute OVA challenge with four IN injections of human recombinant TRAIL (rTRAIL) that preferentially activates death receptor DR5 44 as depicted in Figure 6a . We found that treatment with rTRAIL increased the percentage of annexin-V þ PI -apoptotic cells in the airways as revealed by flow cytometry analysis of BAL cells when compared with non-treated mice (PBS group) (Figure 6b,c) . More importantly, rTRAIL treatment of allergic mice reduced the percentage of lung CD4 þ T cells producing IL-5 (Figure 6d,e) and decreased the number of eosinophils in the BAL (Figure 6f) . These results reinforce the notion that TRAIL signaling acts on inflammatory cells including Th2 cells and eosinophils, thereby attenuating allergic airway inflammation.
DISCUSSION
In this study, we have investigated different regulatory/ suppressor pathways that might underline the resolution of allergic airway inflammation induced by chronic long-term allergen challenges. Our study confirmed and extended this notion by showing that the resolution of allergic inflammation was observed only when chronic OVA challenges were delivered at mucosal surface (airway) but not when administered into serosal peritoneal cavity, indicating that the site where OVA is given is fundamental for the resolution of allergic inflammation induced by long-term allergen challenges. The major pathways of anti-inflammatory mechanisms involve are as follows: (1) production of anti-inflammatory substances such as suppressive cytokines (IL-10, TGF-b; 45, 46 ), bioactive lipids (lipoxin 47 and prostaglandins 48 ), and endogenous mediators (glucocorticoids 49 and acetylcholine 50 ); (2) Induction of regulatory cells (e.g., suppressor lymphocytes such as Treg, Tr1, Th3, regulatory B, and CD8 þ T cells, suppressor macrophages, and mesenchymal cells [51] [52] [53] [54] ; and (3) apoptosis of infiltrating inflammatory cells including effector T cells. 35, 55, 56 All these pathways are highly regulated and implicated in resolution of inflammatory processes and re-establishment of tissue homeostasis and failures in those immunoregulatory mechanisms can result in progression and/or persistence of a range of inflammatory diseases including asthma. [57] [58] [59] Because local inhalational tolerance was first attributed to the emergence and accumulation of Foxp3 þ Treg cells in the airways or local draining lymph nodes, [22] [23] [24] we monitored the appearance of Treg cells during acute and chronic OVA challenges. Our results showed that Foxp3 þ Treg cells were by far more abundant in the airways of acute than in chronic mice, suggesting a Treg-independent mechanism for inhalational tolerance. Also, depletion and/or inactivation of putative CD25
þ Treg cells by an effective anti-CD25 treatment [27] [28] [29] [30] did not restore airway eosinophilia of chronic OVA group. In contrast, anti-CD25 treatment exacerbated allergic airway inflammation of acute OVA group. These results are in line with previous findings showing that anti-CD25 aggravated acute allergic airway inflammation, 22, 27, 60 but, it was ineffective in reversing the tolerant state. 22 Using a OVA model of Th1-and Th2-induced airway inflammation, Niu et al. 26 showed that the vanishing of airway inflammation due to chronic OVA inhalation was associated with a population of TGF-bexpressing macrophages in the lungs. Indeed, we found that TGF-b was expressed in the airways of acute and chronic mice, and that lung CD11c
þ T cells, expressed high levels of LAP. However, anti-TGF-b treatment failed to restore airway allergic inflammation of chronic mice, although it inhibited collagen formation. Our findings are in line with other studies showing that neutralization of TGF-b abrogated airway remodeling. 61, 62 Apoptosis is another highly regulated pathway implicated in resolution of inflammatory processes and re-establishment of tissue homeostasis. We found that increased apoptosis of airway leukocytes, as revealed by annexin-V staining, was associated with the resolution of allergic inflammation. In chronic mice, we found that different cell types including eosinophils, neutrophils, CD4 þ T cells, and antigen-presenting cells, such as MHCII þ CD11b þ cells, were undergoing apoptosis. In chronic group, the extrinsic pathway of apoptosis appeared to be operating, as the expression of apical casp8 and effector casp3 was only induced in this group. In contrast, the expression of casp9, an essential element in the intrinsic or mitochondrially gated pathway of apoptosis was augmented in acute group, reflecting probably a cytokine-induced mitochondrial stress. 63 To further dissect the underlying apoptotic mechanism, we treated the mice with neutralizing mAb directed to key molecules responsible for death-inducing signals. The TRAIL pathway was found to be critically involved in apoptosis because anti-TRAIL, but not anti-FasL or anti-PD-1 treatment restored allergic inflammation. Notably, anti-TRAIL treatment augmented the frequency of activated lung Th2 cells. Keeping with this, previous study showed that frequency of lung CD4 þ T cells expressing the Th2 marker T1/ST2 decreased drastically after chronic OVA challenges. 21 Conversely, treatment of allergic mice with rTRAIL decreased the frequency of Th2 cells producing IL-5. Although FasL expression was clearly augmented in chronic mice, anti-FasL treatment or Fas-deficiency did not affect the resolution of allergic inflammation. It was previously shown that Th2 cells preferentially express TRAIL, whereas Th1 cells express FasL. 64 Our findings are in line with other studies showing the benefits of TRAIL signaling in tumors, 65 bacterial meningitis, 66 experimental autoimmune encephalitis, 67 and neutrophilic inflammation. 68 In humans, TRAIL binds to two death receptors (DR4/ TRAIL-R1 and DR5/TRAIL-R2), whereas in mice it binds to a single death receptor DR5, homolog to human TRAIL-R2. 44 In asthmatic patients, survival of BAL eosinophils was prolonged after allergen provocation and this was correlated with increased expression of DcR2, a TRAIL decoy receptor, and decreased expressions of DR4 and DR5, the canonical human death receptors. 69 Therefore, in humans the effect of TRAIL depends on the interactions and expression of five distinct receptors being detrimental when TRAIL binds to decoy receptors and beneficial when binding to death receptors. 70 In a murine model of asthma, Weckmann et al. 71 showed the role of TRAIL signaling in inducing pathognomic features of asthma, and more recently the same group extended their work by showing that TRAIL signaling in bronchial epithelium upregulated MID1 that promoted pro-allergic innate immune responses via inhibition of protein phosphatase 2A. 40 In line with these findings, we also found high expression of TRAIL and MID1 in acute mice. Even though, we found that repeated IN administration of human rTRAIL, which preferentially activates mouse DR5, but not to mouse DcR1 or mouse DcR2, 44 to allergic mice (acute group) increased apoptosis and attenuated Th2 responses and allergic lung inflammation, indicating that TRAIL treatment can overcome the relative resistance to apoptosis and induce the resolution of acute allergic inflammation. Our findings with rTRAIL conflict with previous study; 40 however, the doses, administration, and animal model are different. We used four low doses of rTRAIL given to allergic mice, whereas previous work used a single-high dose given to naive mice. 40 As mentioned before, TRAIL signaling does not always lead to apoptosis and in some circumstances non-apoptotic TRAIL signaling result in cell proliferation through the activation of nuclear factor-kappa B, protein kinase B, c-Jun N-terminal kinase, p38 mitogenactivated protein kinase, or induction of pro-allergic molecules. 40, 69, 72 It remains to be determined how and when during the passage from acute to chronic OVA challenges proapoptotic molecules increase, whereas anti-apoptotic molecules decrease. Of note is the fact that two molecules involved with TRAIL signaling are differentially expressed in acute or chronic groups. MID1 expression (pro-allergic pathway) is increased in acute group, whereas insulin-like growth factorbinding protein-3, that potentiates TRAIL-induced apoptosis, is increased in chronic group. 42 It follows that TRAIL signaling might have different outcomes according to the status of lung, naive non-challenged, acute or chronically challenged, and the balance of pro-and anti-apoptotic molecules. In fact, based on previous reports, the participation of death receptors and ligands that are members of the TNF receptor superfamily appears to have a dual role in lung inflammation because, depending of physiological or pathological conditions, they can promote inflammation or help in resolution of lung inflammation. 68, 71, [73] [74] [75] Nevertheless, our data clearly demonstrate that TRAIL signaling is sufficient for downmodulation of allergic airway disease in mice, and suggest that deregulation of TRAIL-induced apoptosis could underline the chronic nature of asthma, emphasizing therefore a clinical promise of TRAIL and blockage of pro-allergic molecules in the treatment of asthma. The experiments were performed 24 h after the last OVA challenge. For all experiments, LPS was removed from OVA by two to four cycles of Triton X-114 extractions. The endotoxin level of purified OVA after LPS depletion was below the limit of detection (o0.01 ng ml À 1 ) as determined by Limulus amebocyte lysate QCL-1000 kit (BioWhittaker, Radnor, PA).
Cells. Mice were deeply anesthetized by IV injection of anesthetic solution containing ketamine and xylazine. For BAL cell collection, the tracheae were cannulated and lungs were lavaged with 1 ml of PBS. For lung cell isolation, lungs were first perfused with PBS to remove residual blood. Lung tissue was then minced, digested with 2 mg ml Cytokines and antibodies. Cytokines IL-4, IL-5, IL-10, interferon-g (BD Biosciences), IL-13 (R&D Systems), and TGF-b 1 (Promega, Madison, WI) in the BAL fluid and total IgE (BD Biosciences) in the serum were measured using enzyme-linked immunosorbent assay kits according to the manufacturer's protocol. For determination of OVAspecific IgG1 and IgG2a, serum samples were plated on plates previously coated with OVA (20 mg ml À 1 ; Sigma) and the bound antibodies were detected with goat anti-mouse IgG1 or IgG2a followed by peroxidase-labeled rabbit anti-goat IgG (all from Southern Biotechnology, Birmingham, AL). Purified mouse IgG1 (15H6) and IgG2a (HOPC-1, Southern Biotechnology) were used to estimate the concentration of OVA-specific antibody, as previously described.
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Lung histology. Lungs were prepared for histology by perfusing the animal by the right ventricle with 10 ml of PBS. Lungs were then immersed in 10% phosphate-buffered formalin for 24 h followed by immersion in 70% ethanol until embedded in paraffin. Lung sections with 5 mm were stained with periodic acid-Schiff (PAS)/hematoxylin for evaluation of inflammation and mucus production. The mucus index of PAS-stained bronchi areas was determined using the Metamorph 6.0 (Universal Images, Universal Imaging Corporation, Downingtown, PA) program.
Quantitative RT-PCR. Total RNA from lung cells was isolated with Trizol (Invitrogen, Carlsbad, CA). cDNA was synthesized by RevertAid H Minus M-MuLV-reverse transcriptase (Fermentas, Hanover, MD) and random primers. Real-time PCR analysis was performed on the StepOne Plus (Applied Biosystems, Foster City, CA) using SYBR green mix (Qiagen, Valencia, CA). Relative amounts of mRNA were normalized to b-actin RNA levels within each sample and expressed as relative target abundance by the DDCT method.
Statistical analysis. Statistical significance was assessed by either the two-tailed Student's t-test (two groups) or analysis of variance for multiple groups with a post hoc Tukey test to determine the significances *Po0.05, **Po0.01, and ***Po0.001, all performed using Prism 5.0 software (GraphPad, La Jolla, CA). Data are presented as mean±s.e.m.
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